These initial observations prompted us to evaluate whether re-expression of ERα and the establishment of an alternate nuclear receptor-signalling axis (that is, ERα versus AR) in prostate cancer cells could represent an adaptive mechanism to evade AR-directed therapies. Here, ESR1 is linked to prostate cancer.